ANIP
ANI Pharmaceuticals, Inc.Healthcare · $1.7B market cap
Verdict
Share price
$72.18
close of Oct 3, 2026
Fair value
$63.20
Sticker Price
Payback Price
$25.28
buy price
ANIP is Overpriced: at $72.18 it trades 14% above its fair value of $63.20. Its buy price (Payback Price) is $25.28, 65% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.
How we valued it
Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow ANIP
Get notified when it reaches its buy price of $25.28. Free.
Create a free accountSuperinvestors
None of the investors we track holds ANIP right now. In Q2 2026, 1 sold out. Who we track
Moves in Q2 2026
Sold out: Polen Capital Management
Insider activity
Since Jun 12, 2026: no open-market purchases, 9 sales worth $1.7M and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
CAREY STEPHEN P.
SVP & CFO · 2026-08-31
Sold
$207K
Lalwani Nikhil
PRESIDENT & CEO · 2026-08-25
Sold
$401K
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC. · 2026-08-13
Sold
$38K
Gutwerg Ori
SVP, GENERICS · 2026-08-10
Sold
$243K
CAREY STEPHEN P.
SVP & CFO · 2026-07-29
Sold
$232K
Other filings
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works